Michael J. Katovich
Affiliations: | University of Florida, Gainesville, Gainesville, FL, United States |
Area:
Pharmacology, Molecular Biology, Pharmaceutical ChemistryGoogle:
"Michael Katovich"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Alok S. Pachori | grad student | 2001 | UF Gainesville |
| Caren R. Beck | grad student | 2005 | UF Gainesville |
| Justin L. Grobe | grad student | 2006 | UF Gainesville |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li Calzi S, Cook T, Della Rocca DG, et al. (2019) Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model. Stem Cells International. 2019: 3945850 |
| Sharma RK, Oliveira AC, Kim S, et al. (2018) Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension. Hypertension (Dallas, Tex. : 1979) |
| Rathinasabapathy A, Horowitz A, Horton K, et al. (2018) The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in Physiology. 9: 180 |
| Rathinasabapathy A, Bruce E, Espejo A, et al. (2016) Therapeutic potential of adipose stem cells derived conditioned medium against pulmonary hypertension and lung fibrosis. British Journal of Pharmacology |
| Pei N, Wan R, Chen X, et al. (2015) Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts. Molecular Cancer Therapeutics |
| Qi YF, Zhang J, Wang L, et al. (2015) Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. Journal of Molecular Medicine (Berlin, Germany) |
| Cole-Jeffrey CT, Liu M, Katovich MJ, et al. (2015) ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. Journal of Cardiovascular Pharmacology |
| Bruce E, Shenoy V, Rathinasabapathy A, et al. (2015) Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. British Journal of Pharmacology. 172: 2219-31 |
| Rathinasabapathy A, Horowitz A, Horton K, et al. (2015) C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction European Respiratory Journal. 46 |
| Shenoy V, Yang T, Rathinasabapathy A, et al. (2015) Pp.21.33: The Microbial Metabolite, Butyrate Attenuates Pulmonary Hypertension Journal of Hypertension. 33 |